Stock 300878 ZHEJIANG WECOME PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zhejiang Wecome Pharmaceutical Company Limited

Equities

300878

CNE1000047P9

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
17.72 CNY +1.32% Intraday chart for Zhejiang Wecome Pharmaceutical Company Limited +5.10% -30.15%
Apr. 28 Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 19 Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 4,045 4,246 3,591 3,673
Enterprise Value (EV) 1 3,465 4,047 3,747 3,533
P/E ratio 24.8 x 44 x 80 x -423 x
Yield 1.99% 1.02% - -
Capitalization / Revenue 6.5 x 6.71 x 6.76 x 7.07 x
EV / Revenue 5.56 x 6.39 x 7.05 x 6.8 x
EV / EBITDA 25,676,927 x 41,467,293 x 57,976,027 x 308,517,906 x
EV / FCF -23.8 x -13.3 x -10.5 x 18.7 x
FCF Yield -4.2% -7.53% -9.55% 5.34%
Price to Book 2.93 x 3.04 x 2.57 x 1.85 x
Nbr of stocks (in thousands) 144,790 144,790 144,790 144,790
Reference price 2 27.94 29.32 24.80 25.37
Announcement Date 3/30/21 4/28/22 4/27/23 4/19/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 577.7 641.8 622.8 633 531.3 519.6
EBITDA - 135.4 134.9 97.6 64.63 11.45
EBIT 1 94.69 127.9 122.8 83.62 33.78 -22.6
Operating Margin 16.39% 19.92% 19.72% 13.21% 6.36% -4.35%
Earnings before Tax (EBT) 1 103.4 147.6 158.7 100 57.75 -5.786
Net income 1 87.78 126 135.8 96.5 44.44 -8.039
Net margin 15.2% 19.63% 21.81% 15.25% 8.37% -1.55%
EPS 2 0.8056 1.161 1.128 0.6667 0.3100 -0.0600
Free Cash Flow 1 -140.4 -58.32 -145.4 -304.9 -357.9 188.6
FCF margin -24.31% -9.09% -23.34% -48.18% -67.37% 36.3%
FCF Conversion (EBITDA) - - - - - 1,647.37%
FCF Conversion (Net income) - - - - - -
Dividend per Share - - 0.5556 0.3000 - -
Announcement Date 6/28/19 3/6/20 3/30/21 4/28/22 4/27/23 4/19/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 4.04 - - 156 -
Net Cash position 1 13 - 581 198 - 140
Leverage (Debt/EBITDA) - 0.0299 x - - 2.419 x -
Free Cash Flow 1 -140 -58.3 -145 -305 -358 189
ROE (net income / shareholders' equity) 25.1% 27.6% 14.3% 6.91% 3.2% -0.44%
ROA (Net income/ Total Assets) 10.6% 10.5% 6.13% 3.15% 1.17% -0.71%
Assets 1 831.2 1,196 2,216 3,067 3,797 1,127
Book Value Per Share 2 3.630 4.790 9.540 9.650 9.660 13.70
Cash Flow per Share 2 0.7700 1.480 4.110 1.940 1.120 3.250
Capex 1 173 115 152 171 248 139
Capex / Sales 29.9% 17.91% 24.46% 27.03% 46.76% 26.81%
Announcement Date 6/28/19 3/6/20 3/30/21 4/28/22 4/27/23 4/19/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
ZHEJIANG WECOME PHARMACEUTICAL COMPANY LIMITED Stock Zhejiang Wecome Pharmaceutical Company Limited
-30.15% 355M
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300878 Stock
  4. Financials Zhejiang Wecome Pharmaceutical Company Limited